25 reports

Immunohematology, ##(##), ##-## < PMID> ##< / PMID>.

  • Renal Disease
  • Japan
  • United States
  • Amgen Inc.
  • Roche Group
  • https://clinicaltrials.gov/ct2/show/results/NCT01537042?term=NCT01537042&rank=1 =X70156#outcome 1

TOTAL, SERIOUS ADVERSE EVENTS ABDOMINAL PAIN CHEST PAIN GASTROINTESTINAL INFECTION FOOT FRACTURE ANXIETY DYSPNOEA PLACEBO ROTIGOTINE ##/ ## (##. ##%) ##/ ## (##. ##%) ##/ ## (##. ##%) ##/ ## (##. ##%) ##/ ## (##. ##%) ##/ ## (##. ##%) ##/ ## (##. ##%) ##&

  • Renal Disease
  • United States
  • World
  • Keryx Biopharmaceuticals, Inc.
  • Novartis AG

WE ARE ALSO ACTIVE IN THE INFECTION, NEUROSCIENCE AND GASTROINTESTINAL (ING) DISEASE AREAS.

  • Renal Disease
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles

No grade ## gastrointestinal adverse events were reported.

  • Renal Disease
  • United States
  • World
  • Product Initiative
  • CTI BioPharma Corp.

No grade ## gastrointestinal adverse events were reported.

  • Renal Disease
  • Therapy
  • United States
  • World
  • CTI BioPharma Corp.

Gastrointestinal events were the frequent adverse event leading to withdrawal during XP## treatment.

  • Chronic Disease
  • Renal Disease
  • United States
  • Product Initiative
  • RPI
  • Renal Diseases, Global, Overall
  • Renal Diseases, Global, Pipeline Programs Targeting Connective Tissue Growth Factor, 2017

In Vivo; ##(##): ##-## Okamura DM, et al. (2011).

  • Chronic Disease
  • Renal Disease
  • World
  • Deals & Alliance
  • Galectin Therapeutics Inc.
  • CALCIUM SUCCINATE - DRUG PROFILE
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY NOVARTIS AG, H2 2017

No grade ## gastrointestinal adverse events were reported.

  • Diabetes
  • Renal Disease
  • United States
  • Company
  • Product Initiative
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY IC-MEDTECH INC, H1 2018
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY IPSEN SA, H1 2018

It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases.

  • Renal Disease
  • Therapy
  • United States
  • Company
  • Product Initiative
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY NOVATARG THERAPEUTICS INC, H2 2017
  • POLYCYSTIC KIDNEY DISEASE - PIPELINE BY IC-MEDTECH INC, H2 2017

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ##, ## and ## respectively.

  • Renal Disease
  • Therapy
  • United States
  • Company
  • Product Initiative

The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Renal Disease
  • Therapy
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.

The molecules developed by companies in Phase III, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Renal Disease
  • Therapy
  • United States
  • Product Initiative
  • ChemoCentryx, Inc.
  • CALCIUM SUCCINATE - DRUG PROFILE

No grade ## gastrointestinal adverse events were reported.

  • Pharmaceutical
  • Renal Disease
  • United States
  • World
  • CTI BioPharma Corp.
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY NOVARTIS AG

Patiromer is not absorbed and acts within the gastrointestinal tract.

  • Chronic Disease
  • Renal Disease
  • United States
  • Company
  • Product Initiative
  • Target

Further important advantages of ADV## which were demonstrated in the study were its good palatability, ease of administration and gastrointestinal tolerability.

  • Clinical Trial
  • Drug Discovery And Development
  • Hormone
  • Renal Disease
  • World
  • Clinical Trial profile. 893 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Pharmaceutical
  • Renal Disease
  • World

No grade ## gastrointestinal adverse events were reported.

  • Diabetes
  • Renal Disease
  • United States
  • Company
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Hospital
  • Renal Disease
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Hormones
  • Pharmaceutical
  • Renal Disease
  • World

- Research and Development Overview Angion Biomedica Corp. has promising clinical drug candidates for ## major therapeutic areas, Cardiovascular, Central Nervous System, Gastrointestinal, Oncology, Respiratory, Immunology, Genito Urinary System And Sex Hormones and Toxicology.

  • Heart Attack
  • Renal Disease
  • United States
  • Product Initiative
  • Angion Biomedica Corp.
  • CALCIUM SUCCINATE - DRUG PROFILE
  • CHRONIC KIDNEY DISEASE (CHRONIC RENAL FAILURE) - PIPELINE BY NOVARTIS AG, H1 2017

No grade ## gastrointestinal adverse events were reported.

  • Diabetes
  • Genitourinary System Disease
  • Renal Disease
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Endocrine Disease
  • Renal Disease
  • Therapy
  • World
  • Product Initiative

PRRT is often used to treat aggressive endocrine cancer tumors in the gastrointestinal tract and the lungs.

  • Hospital
  • Renal Disease
  • United States
  • Product Initiative
  • Quark

The prominent features of this report are - ##.

  • Endocrine Disease
  • Renal Disease
  • Therapy
  • World
  • Product Initiative

It is an anti-neoplastic and a gastrointestinal agent.

  • Pharmaceutical
  • Renal Disease
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.